The HCC tissue-specific RNAi system targeting Atg5 gene was constructed and the efficacy of the system for sensitizing HCC cells to sorafenib treatment was examined in vitro and in vivo. This evidence concerns the gene ATG5 and hepatocellular carcinoma.